EP2753273B1 - Gastric or peritoneal delivery of frozen mist to induce therapeutic hyperthermia - Google Patents

Gastric or peritoneal delivery of frozen mist to induce therapeutic hyperthermia Download PDF

Info

Publication number
EP2753273B1
EP2753273B1 EP12829249.7A EP12829249A EP2753273B1 EP 2753273 B1 EP2753273 B1 EP 2753273B1 EP 12829249 A EP12829249 A EP 12829249A EP 2753273 B1 EP2753273 B1 EP 2753273B1
Authority
EP
European Patent Office
Prior art keywords
patient
mixture
gas stream
flowing gas
frozen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP12829249.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2753273A1 (en
EP2753273A4 (en
Inventor
Amir Belson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qool Therapeutics Inc
Original Assignee
Qool Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qool Therapeutics Inc filed Critical Qool Therapeutics Inc
Publication of EP2753273A1 publication Critical patent/EP2753273A1/en
Publication of EP2753273A4 publication Critical patent/EP2753273A4/en
Application granted granted Critical
Publication of EP2753273B1 publication Critical patent/EP2753273B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/0085—Devices for generating hot or cold treatment fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/02—Compresses or poultices for effecting heating or cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/0063—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/0069—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit with return means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0095—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/02—Compresses or poultices for effecting heating or cooling
    • A61F2007/0225—Compresses or poultices for effecting heating or cooling connected to the body or a part thereof
    • A61F2007/0233—Compresses or poultices for effecting heating or cooling connected to the body or a part thereof connected to or incorporated in clothing or garments
    • A61F2007/0234—Compresses or poultices for effecting heating or cooling connected to the body or a part thereof connected to or incorporated in clothing or garments for the upper part of the trunk, e.g. bodice
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A61F2007/126—Devices for heating or cooling internal body cavities for invasive application, e.g. for introducing into blood vessels

Definitions

  • the present invention relates generally to apparatus for selective modification and control of a patient's body temperature. More particularly, it relates to relatively non-invasive and field operable systems of lowering a patient's body temperature by heat exchange within the patient's peritoneum. Peritoneal heat exchange provides the benefit of extremely rapid cooling of the patient's target organs such as the heart and brain as well as facilitating global patient body temperature reduction to therapeutically effective temperatures.
  • the heat exchange medium of the present invention is a chilled gaseous fluid suspension of frozen ice particles.
  • Man is considered to be a tropical animal. Normal functioning of the human animal requires a body temperature of approximately 37 degrees Celsius (98.6 degrees Fahrenheit). The body can self-compensate for small upward or downward variations in temperature through the activation of a built-in thermoregulatory system, controlled by temperature sensors in the skin. The response to an upward variation in body temperature is the initiation of perspiration, which moves moisture from body tissues to the body surface. When the moisture reaches the surface it evaporates, carrying with it a quantity of heat. The explanation for a person becoming thirsty when exposed to a hot environment for a period of time is that fluids lost due to perspiration must be replaced. The response to a downward variation in body temperature is shivering, which is the body's attempt to generate heat. Shivering is an involuntary contraction and expansion of muscle tissue occurring on a large scale. This muscle action creates heat through friction.
  • Hypothermia is defined as a core temperature of less than 35 degrees Celsius. Hypothermia is also considered the clinical state of subnormal temperature when the body is unable to generate sufficient heat to effectively maintain functions. Many variables contribute to the development of hypotherthermia. Age, health, nutrition, body size, exhaustion, exposure, duration of exposure, wind, temperature, wetness, medication and intoxicants may decrease heat production, increase heat loss, or interfere with thermostability. The healthy individual's compensatory responses to heat loss via conduction, convection, radiation, evaporation and respiration may be overwhelmed by exposure. Medications may interfere with thermoregulation. Acute or chronic central nervous system processes may decrease the effectiveness of thermoregulation. Mild Hypothermia is when the core temperature is 34-35 degrees Celsius. The patient is still alert and able to help him/herself and intense shivering begins. The patient's movements, however, become less coordinated and the coldness creates some pain and discomfort.
  • Moderate hypothermia is when the patient's core temperature is 31-33 degrees Celsius. Shivering slows or stops, muscles begin to stiffen and mental confusion and apathy sets in. Speech becomes slow, vague and slurred, breathing becomes slow and shallow, and drowsiness and strange behavior may occur.
  • Severe hypothermia is when the core temperature drops below 31 degrees Celsius. Skin is cold, may be bluish-gray in color, eyes may be dilated. The patient is very weak, displays a marked lack of coordination, slurred speech, appears exhausted, may appear to be drunk, denies there is a problem and may resist help. There is a gradual loss of consciousness. There may be little or no apparent breathing, the patient may be very rigid, unconscious, and may appear dead.
  • Simple methods for treating hypothermia have been known since very early times. Such methods include wrapping the patient in blankets, administering warm fluids by mouth, and immersing the patient in a warm water bath. Even these simple methods may be effective if the hypothermia is not too severe. These simple methods are limited in their effectiveness however. Wrapping the patient in blankets ultimately depends on the patient's own production of heat to rewarm his body. In even moderate cases of hypothermia, or in the case of an ill or injured patient, the patient may simply be too weak or exhausted to produce sufficient heat. Oral administration of a warm fluid requires that the patient be conscious and capable of swallowing the fluid.
  • Recent medical reports have described the use of controlled hypothermia as a means to reduce oxygen consumption of tissue, such as the heart muscle and the brain during decreased perfusion that occurs as a result of myocardial infarction and ischemic stroke (respectively), which leads to reduced damage and decrease of the infarcted area.
  • Medical reports have also described the prophylactic use of controlled hypothermia during cardiac surgery or interventional cardiology procedures for reducing damage from ischemia and/or embolization in the heart and brain during and after the procedure.
  • Cooling blankets offer a portable easily deployable means of chilling a patient but the body's own thermoregulatory mechanisms counteract the cooling mechanisms of such blankets through vasoconstriction.
  • cooling blankets are not able to induce hypothermia in the patient in clinically relevant time span.
  • Ice baths are capable of reducing patient body temperature rapidly due to the large thermal gradient and large specific heat capacity of the cooling medium.
  • ice baths are not portable are inconsistent with necessary concurrent interventions required for treatment of MI and stroke, such as balloon angioplasty.
  • Peritoneal catheters equipped with heat exchangers are capable of rapid cooling of the patient but the size required of such catheters makes their deployment invasive. Additionally such catheterizations require skilled technicians and must be performed in the hospital. By the time a patient has reached a hospital much critical time has been lost.
  • Field deployable respiratory cooling systems that operate by using the body's own lungs as heat exchangers and use a gaseous fluid suspension of frozen particles as a convective cooling medium are capable of inducing hypothermia in clinically relevant time spans.
  • a gaseous fluid suspension of frozen particles as a convective cooling medium are capable of inducing hypothermia in clinically relevant time spans.
  • respiratory cooling mechanisms have yet to match cooling rates of peritoneal cooling.
  • Body temperature reducing method involves administering nebulized mist at temperature below body temperature of patient until patient's temperature 2 is reduced.
  • US20030136402 Method for altering the body temperature of a patient using a nebulized mist--Body temperature reducing method involves administering nebulized mist at temperature below body temperature of patient until patient's temperature is reduced.
  • Noninvasive method for increasing or decreasing the body temperature of a patient --Increasing or decreasing body temperature for treating e.g. hemorrhagic shock comprises administering oxygen and sulfur hexafluoride gas mixture by hyperventilation.
  • EP1089743 Composition containing sulfur hexafluoride and oxygen, for increasing or decreasing the body temperature of a patient--Increasing or decreasing body temperature for treating e.g. hemorrhagic shock comprises administering oxygen and sulfur hexafluoride gas mixture by hyperventilation.
  • WO9966938 Composition containing sulfur hexafluoride and oxygen, for increasing or decreasing the body temperature of a patient--Increasing or decreasing body temperature for treating e.g. hemorrhagic shock comprises administering oxygen and sulfur hexafluoride gas mixture by hyperventilation.
  • Hypothermia-inducing treatment method for patient in cardiac arrest involves performing continuous administering of phase-change particulate slurry to patient in cardiac arrest until state of hypothermia is induced to patient.
  • WO0108593 Method for inducing hypothermia--Improvement of a cardiac arrest patient's outcome by pre-hospital administration of a phase-change particulate slurry internally until a state of hypothermia is induced.
  • US20030131844 Inducing hypothermia and rewarming using a helium-oxygen mixture--Composition useful for treating ischemic event by inducing hypothermia comprises a gas mixture comprising helium and oxygen having temperature significantly different than normal human body temperature.
  • WO 2005/079108 describes a system that generates particles of mist, freezes the mist particles and delivers a mixture of a gas and the solid mist particles to an external application.
  • WO 2009/009540 describes a method of providing hypothermia in a patient including steps of inserting a fluid delivery member into a peritoneal cavity of the patient, delivering hypothermia fluid from a fluid source into the peritoneal cavity through the delivery member and limiting fluid pressure within the peritoneal cavity without providing feedback control to the fluid source.
  • a phase change solution such as a slurry of ice, may be used within the cavity.
  • the present invention is set out in the appended claims. Described herein are methods and systems for the improved cooling of a patient to selectively induce hypothermia.
  • the methods and systems rely on producing a flowing gas stream, which carries an entrained mist or suspension of frozen solid particles.
  • the flowing gas stream is passed by or over a body surface which is not part of the patient's respiratory system, and at least some of the frozen mist particles will melt such that the resulting phase change absorbs large amounts of the body heat, thus reducing the body temperature.
  • the enthalpic heat absorption resulting from the phase change from the frozen particles melting (or in some cases, subliming) provides much greater heat absorption than would be possible using a cooled gas stream by itself. Cooling of body surfaces other than those in the respiratory system is also advantageous in that many such surfaces can be easily accessed and it is not necessary that the patient be breathing at the time of the treatment.
  • Described herein is a method for cooling the patient that comprises generating a mist of frozen solid particles in a flowing gas stream.
  • the flowing gas stream is passed over a targeted body surface which is not part of the patient's respiratory system.
  • the solid particles melt or sublime to absorb body heat to lower the patient's body temperature.
  • the body surface will often be part of a body cavity, typically being within a patient's abdominal cavity or stomach. Alternatively, the body surface may be an external surface, such as the skin over the patient's torso.
  • the flowing gas stream When cooling a body cavity, the flowing gas stream is typically passed through an abdominal wall and the gas stream (which would otherwise accumulate within the body cavity) is also removed through the abdominal wall.
  • inlet and outlet conduits are positioned through the abdominal wall, and the flowing gas stream is introduced through the inlet conduit and removed through the outlet conduit.
  • separate inlet and outlet conduits will be used and introduced through opposed locations on the abdominal wall in order to promote more complete circulation within the body cavity.
  • the inlet and outlet conduits may be combined in a single structure which is introduced through a single penetration in the abdominal wall.
  • the patient's skin or torso is exposed.
  • the skin or torso will usually be covered with a jacket or similar structure which covers at least a portion of the torso and which constrains the flowing gas stream so that it effectively cools the patient's skin.
  • the jacket may be in the form of a "bladder" or other sealed system, in which case the flowing gas stream would recirculate within a sealed exterior and the transfer would take place over a wall of the jacket. In other cases, the jacket may be opened so that the flowing gas stream is allowed to directly contact the skin for a more efficient heat transfer.
  • the mist of frozen particles is typically generated by cooling the flowing gas stream and injecting liquid droplets into the stream so that they freeze in situ. Cooling the gas may be effected in conventional manners, often by expansion through an expansion valve in order to cause adiabatic cooling. Optionally, the droplets or liquid which is formed into the droplets may also be cooled before they are injected into the flowing gas stream.
  • the liquid and gas may comprise any suitable, biocompatible fluids which provide for significant enthalpic heat absorption where the frozen particles will melt or sublime at body temperature. Most commonly, the liquid will be water and the gas will be air, nitrogen, heliox, HF 6 , carobon dioxide or another common gas.
  • the gas particles could be frozen carbon dioxide (dry ice) which would sublime when exposed to the body surface in order to absorb heat.
  • Dry ice could optionally be provided as a solid mass, where the mass is broken down into small particles which can be injected into a flowing gas stream (therefore the gas stream need not be cooled or as cooled).
  • a system for cooling a patient that comprises a generator which produces a mist of frozen particles in a flowing gas stream.
  • the system further comprises a mechanism for directing the flowing gas stream to a body surface which is not part of a patient's respiratory system.
  • the frozen mist generator may be created without freezing a liquid in a chilled gas stream. Rather the frozen particle mist is created in a separate production apparatus such as a nebulizer or ice fog machine.
  • An ice fog machine is typically capable of chilling a solution of air with high humidity below the freezing point of water. Small ice crystals nucleate to form a suspension of frozen particle mist of small ice particles.
  • the frozen particle mist may then be further mixed with a chilled gaseous fluid stream an un-chilled gaseous fluid stream or used on its own.
  • the generator may comprise a chiller for cooling the gas, a pump for producing the flowing gas stream, and a nozzle for injecting a liquid into the cooled, flowing gas stream.
  • the directing means comprise of a tubular member for penetrating an abdominal wall to introduce the flowing gas stream to an abdominal cavity or stomach. Alternately, first and second tubular elements will be employed for both introducing a gas stream and for removing the gas stream from the cavity. Alternatively, the directing means can comprise a jacket for placing over the patient to direct a flow over the patient's torso.
  • a chilled gaseous fluid is produced using a chilled fluid source which may comprise a vessel storing a gas in a compressed state and/or refrigerated state. Adiabatic expansion of the gas results in a moving stream of further chilled gas,
  • the gas typically comprises air, HELIOX (a mixture of 20% O 2 and 80% He 2 ), or sulfur hexafluoride (HF 6 ) but may further comprise any biocompatible gas with specific heat capacity sufficient enough for cooling operations.
  • the chilled gaseous fluid may alternatively be produce by an suitable refrigeration system, such electrically powered refrigerators, gas or propane powered refrigerators, or any suitable gas refrigeration's system known in the art.
  • the frozen particles typically comprise ice and are produced by the introduction of a spray of a second fluid, typically liquid water, from a fluid source into the stream of the chilled gas.
  • the cooling gas having been chilled to below the freezing temperature of water freezes the water droplets.
  • the particles typically comprise ice it should be appreciated that any biocompatible fluid with an appropriate freezing point, heat capacity and enthalpy of fusion may be used instead of liquid water.
  • the suspension of frozen particles acts to augment the cooling properties of the gas/ice mixture.
  • the latent heat required to overcome the enthalpy of fusion to melt the ice particles ensures that the cooling media temperature remains close to 0°C and the preservation of the thermal gradient across the tissue media interface. Removing heat from the patient rapidly requires maintaining a large temperature gradient between the tissues being cooled and the cooling media. Additionally, the phase change required to melt the frozen particle mist increases the total amount of energy the chilled fluid and mist mixture can remove from the patient. The total power removed from system is proportional to the rate of addition of ice particles as shown by the calculations in Table 1 shown below.
  • FIG. 1 One exemplary embodiment of the present disclosure is shown in figure 1 .
  • a main conduit 110 is shown in a patient penetrating the patient's abdominal wall AW in order to distribute a mixture of chilled gas and frozen mist into the abdominal cavity.
  • a distal end 112 of the main conduit 110 located in a peritoneum P.
  • a chilled fluid source 101 is connected to a main lumen 113 of the main conduit 110.
  • a fluid port 114 allows for the introduction of a liquid from a second fluid source 102.
  • the fluid port 114 is show proximal to the abdominal wall however it should be appreciated that the fluid port 114 may be located distal to the abdominal wall.
  • the fluid injection port 114 may be adapted to atomize the liquid, such that a mist of small liquid droplets forms as the fluid is introduced into the chilled gas flow.
  • the small droplets freeze as they exchange thermal energy with the chilled gaseous fluid stream 103 to form a frozen particle suspension (a mist) 104.
  • the mixture 105 of chilled gaseous fluid 103 and frozen particle mist 104 exits the main conduit 110 into the abdominal cavity to chill tissues therein.
  • a sensor package 106 may be used to monitor at least one of the following: patient body temperature, abdominal cavity body temperature, target organ temperature, chilled gaseous fluid flow rate, or liquid fluid introduction rate.
  • Data measured by sensor package 106 is used may be used by a processor/controller 107 to modify the production and flow rate of the mixture 105, the flow and temperature of the gaseous fluid stream 103 in order to control the patient's temperature two within targeted therapeutic ranges. It should be understood that the fluid stream 103 and mixture 105 may not always be introduced into the patient's abdominal cavity in a continuous fashion. If the processor/controller 107 receives data from the sensor package 106 that indicates the temperature of patient's tissues are falling below the designated therapeutic range into potentially harmful ranges then the processor/controller may alter the characteristics of the gaseous fluid stream 103 or the mixture 105 or stop or retard the flow of either the gaseous fluid stream and/or the mixture 105.
  • FIG. 2 Another embodiment of the disclosure is shown in figure 2 .
  • a main conduit 210 is shown in a patient penetrating the patient's abdominal wall AW and placed into the patient's peritoneum P.
  • the main conduit 210 comprises an inflow lumen 211 and an outflow lumen 212.
  • the inflow lumen 211 is connected to a chilled gaseous fluid source 201.
  • a stream of chilled gaseous fluid 203 flows through the inflow lumen 211 where it encounters a spray of liquid, typically water, introduced by the a liquid source 202 at a fluid injection port 214.
  • the spray of liquid is frozen by the chilled gaseous fluid stream into a mist 204 of small frozen particles (typically ice).
  • the mixture 205 of chilled gaseous fluid 203 and mist 204 proceeds from the inflow lumen 211 into the abdominal cavity of the patient to cool the patient. Thermal energy is removed from the patient as the mixture 205 is heated and the frozen particles of mist 204 melt. To facilitate further cooling the mixture 205 may be extracted out of the abdominal cavity through outflow lumen 212, which is optionally connected to a vacuum source 208. Evacuation of mixture 205 from the abdominal cavity may be accomplished via the vacuum source 208 or via passive means relying on positive pressure created in the abdominal cavity. The extraction of mixture 205 from the abdominal cavity ensures that more of mixture 205 can continue to flow through inflow lumen 211 and that the mixture 205 remains sufficiently cold relative to the patient to ensure continual rapid cooling of the patient.
  • Inflow conduit 211 and outflow conduit 212 each have independent valves 221 and 222 respectively. This allows introduction of the mixture 205 and extraction of the mixture 205 to occur independently or simultaneously. Inflow lumen 211 and outflow lumen 212 may have different lengths, such that mixture 205 is introduced into the abdominal in a different location than mixture 205 is removed from the abdominal cavity. This may be done in an effort to prevent shunting and to better distribute the mixture 205 throughout the abdominal cavity.
  • a sensor package 206 may be used to monitor at least one of the following: patient body temperature, abdominal cavity body temperature, target organ temperature, chilled gaseous fluid flow rate, or liquid fluid introduction rate.
  • a processor/controller 207 is connected to the chilled gaseous fluid source 201, liquid source 202, and sensor package 206, and vacuum source 208 and is capable of controlling the functioning of any of these elements. Data measured by sensor package 206 is used may be used by a processor/controller 207 to modify the production and flow rate of the mixture 205, the amount of frozen particle mist in mixture 205, and the extraction rate of mist 205 from the abdominal cavity, and actuation of valving 221 and 222 in order to control the patient's temperature to within targeted therapeutic ranges.
  • processor/controller 207 is able to independently modify the flow rate of chilled gaseous fluid 202, rate of mist 204 generation and flow rate of mixture 205, as well as extraction rate of mixture 205 from the abdominal cavity. At any point, the flow of chilled gaseous fluid 202, generation of mist 204 and flow mixture 205 into the abdominal cavity and extraction of the mixture 205 from the abdominal cavity may be independently stopped by the processor/controller 207.
  • FIG. 3 An embodiment of the invention is shown in figure 3 .
  • Two needles are shown in a patient, an inflow needle 311 and an outflow needle 312.
  • the inflow needle 311 and outflow needle 312 are shown inserted into the patient's abdominal cavity penetrating the patient's abdominal wall AW their respective ends in the peritoneum P.
  • the inflow needle 311 and outflow needle 312 are veress needles designed to reach the peritoneum without damaging internal organs IO.
  • any safety needle or surgical access needle suitable for such use known to the art may be used.
  • the inflow needle is connected to a chilled gaseous fluid source 301 which produces a stream of chilled gas 303.
  • a Fluid injection port 314 in the inflow needle 311 connects the inflow needle 311 to a liquid fluid source 302 and produces a spray of liquid which freezes into a mist 304 of frozen particles to produce a mixture 305 of chilled gaseous fluid and frozen particle mist.
  • the mixture 305 then exits the inflow needle into the abdominal cavity, typically in the peritoneum P.
  • the mixture 305 is shown flowing over internal organs IO extracting heat 350 from said internal organs IO, it is understood that heat is also extracted from all tissues in the abdominal cavity that come in contact with the mixture 305. In the process of removing heat from a patient's internal organs the mixture 305 will become heated and frozen particles in the mist 304 melt.
  • the mixture 305 is extracted from the abdominal cavity through the outflow needle 312, which is optionally connected to a vacuum source 308.
  • Vacuum source 308 may be used to aid in extraction of the mixture 305, alternatively passive extraction relying on positive partial pressure in the abdominal cavity may be used instead.
  • Inflow needle 311 and outflow needle 312 are each equipped with independent valves 321 and 322 respectively to aid in controlling the flowrate and extraction rate of mixture 305.
  • a sensor package 306 may be used to monitor at least one of the following: patient body temperature, abdominal cavity body temperature, target organ temperature, chilled gaseous fluid flow rate, or liquid fluid introduction rate
  • a processor/controller 307 is connected to the chilled gaseous fluid source 301, liquid source 302, and sensor package 306, and vacuum source 308 and is capable of controlling the functioning of any of these elements. Data measured by sensor package 306 is used may be used by a processor/controller 307 to modify the production and flow rate of the mixture 305, the amount of frozen particle mist in mixture 305, and the extraction rate of mist 305 from the abdominal cavity, and actuation of valving 321 and 322 in order to control the patient's temperature to within targeted therapeutic ranges.
  • processor/controller 307 is able to independently modify the flow rate of chilled gaseous fluid 302, rate of mist 304 generation and flow rate of mixture 305, as well as extraction rate of mixture 305 from the abdominal cavity. At any point, the flow of chilled gaseous fluid 302, generation of mist 304 and flow mixture 305 into the abdominal cavity and extraction of the mixture 305 from the abdominal cavity may be independently stopped or restarted by the processor/controller 307.
  • FIG. 4 Another embodiment of the invention is shown in figure 4 .
  • Two catheters are shown in a patient's abdominal cavity an inflow catheter 411 and an outflow catheter 412.
  • the inflow catheter 411 and outflow catheter 412 are shown inserted into the abdominal cavity penetrating the abdominal wall AW their respective ends in the peritoneum P.
  • the inflow catheter and outflow catheter may optionally be inserted over veress needles.
  • the inflow needle is connected to a chilled gaseous fluid source 401 which produces a stream of chilled gas 403.
  • a Fluid injection port 414 in the inflow catheter 411 connects the inflow catheter 411 to a liquid fluid source 402 and produces a spray of liquid which freezes into a mist 404 of frozen particles to produce a mixture 405 of chilled gaseous fluid and frozen particle mist.
  • the mixture 405 then exits the inflow catheter into the abdominal cavity, typically in the peritoneum P.
  • the mixture 405 is shown flowing over internal organs IO extracting heat 450 from said internal organs IO, it is understood that heat is also extracted from all tissues in the abdominal cavity that come in contact with the mixture 405. In the process of removing heat from a patient's internal organs the mixture 405 will become heated and frozen particles in the mist 404 melt.
  • the mixture 405 is extracted from the abdominal cavity through the outflow catheter 412, which is optionally connected to a vacuum source 408.
  • Vacuum source 408 may be used to aid in extraction of the mixture 405, alternatively passive extraction relying on positive partial pressure in the abdominal cavity may be used instead.
  • Inflow catheter 411 and outflow catheter 412 are each equipped with independent valves 421 and 422 respectively to aid in controlling the flowrate and extraction rate of mixture 405.
  • a sensor package 406 may be used to monitor at least one of the following: patient body temperature, abdominal cavity body temperature, target organ temperature, chilled gaseous fluid flow rate, or liquid fluid introduction rate.
  • a processor/controller 407 is connected to the chilled gaseous fluid source 401, liquid source 402, and sensor package 406, and vacuum source 408 and is capable of controlling the functioning of any of these elements. Data measured by sensor package 406 is used may be used by a processor/controller 407 to modify the production and flow rate of the mixture 405, the amount of frozen particle mist in mixture 405, and the extraction rate of mist 405 from the abdominal cavity, and actuation of valves 421 and 422 in order to control the patient's temperature to within targeted therapeutic ranges. It should be understood that processor/controller 407 is able to independently modify the flow rate of chilled gaseous fluid 402, rate of mist 404 generation and flow rate of mixture 405, as well as extraction rate of mixture 305 from the abdominal cavity. At any point, the flow of chilled gaseous fluid 402, generation of mist 304 and flow mixture 405 into the abdominal cavity and extraction of the mixture 405 from the abdominal cavity may be independently stopped or restarted by the processor/controller 407.
  • FIG. 5 Another embodiment of the invention is shown in figure 5 .
  • Two catheters are shown an inflow conduit 511 and an outflow conduit 512.
  • the inflow conduit 411 and outflow conduit 412 are shown inserted into a patient's abdominal cavity penetrating the abdominal wall AW, their respective ends in the peritoneum P.
  • the inflow conduit 511 and outflow conduit 512 may each be either a needle or catheter.
  • the inflow conduit is connected to a chilled gaseous fluid source 501 which produces a stream of chilled gas 503.
  • a Fluid injection port 514 in the inflow conduit 511 connects the inflow catheter 511 to a liquid fluid source 502 and produces a spray of liquid which freezes into a mist 504 of frozen particles to produce a mixture 505 of chilled gaseous fluid and frozen particle mist.
  • the mixture 505 then exits the inflow catheter into the abdominal cavity, typically in the peritoneum P.
  • the mixture 505 is shown flowing over internal organs IO extracting heat 550 from said internal organs IO, it is understood that heat is also extracted from all tissues in the abdominal cavity that come in contact with the mixture 505. In the process of removing heat from a patient's internal organs the mixture 505 will become heated and frozen particles in the mist 504 melt.
  • the mixture 505 is extracted from the abdominal cavity through the outflow catheter 512, which is optionally connected to a vacuum source 508.
  • Vacuum source 508 may be used to aid in extraction of the mixture 505, alternatively passive extraction relying on positive partial pressure in the abdominal cavity may be used instead.
  • Inflow conduit 511 and outflow conduit 512 are each equipped with independent valves 521 and 522 respectively to aid in controlling the flowrate and extraction rate of mixture 505.
  • a turbulent flow 520 of mixture 505 is created in the abdominal cavity. The turbulent flow enhances the rate of heat transfer in the peritoneum by ensuring that the fluid layer of mixture 505 contacting the internal organs IO is well mixed with the rest of the mixture 505 present in the abdominal cavity.
  • the turbulent flow may be generated by means well known in the art such as modified tips for conduits 511 and 512 or by controlling the physical arrangement of conduits 511 and 512 in the abdominal cavity along with the flow rate and the pressure of mixture 505 entering and exiting the abdominal cavity through conduits 511 and 512 respectively.
  • a sensor package 506 may be used to monitor at least one of the following: patient body temperature, abdominal cavity body temperature, target organ temperature, chilled gaseous fluid flow rate, or liquid fluid introduction rate.
  • a processor/controller 507 is connected to the chilled gaseous fluid source 501, liquid source 502, and sensor package 506, and vacuum source 508 and is capable of controlling the functioning of any of these elements.
  • Data measured by sensor package 506 is used may be used by a processor/controller 507 to modify the production and flow rate of the mixture 505, the amount of frozen particle mist in mixture 505, and the extraction rate of mist 505 from the abdominal cavity, and actuation of valving 521 and/ 522 in order to control the patient's temperature to within targeted therapeutic ranges.
  • processor/controller 507 is able to independently modify the flow rate of chilled gaseous fluid 502, rate of mist 504 generation and flow rate of mixture 505, as well as extraction rate of mixture 505 from the abdominal cavity. At any point, the flow of chilled gaseous fluid 502, generation of mist 504 and flow mixture 505 into the abdominal cavity and extraction of the mixture 505 from the abdominal cavity may be independently stopped or restarted by the processor/controller 507.
  • a suit 630 is shown.
  • the suit has tightening zones 631 around the neck, belly and arms to create a substantial seal against the skin of a patient's torso.
  • the suit has at least one inflow port 611, (multiple inflow ports shown) connected to a chilled gaseous fluid source 601 and at least one outflow port 612 (multiple outflow ports shown) connected to a vacuum source 608.
  • a fluid liquid source 602 provides a liquid fluid spray that frozen into a frozen particle mist 604 in a stream if a chilled gaseous fluid 603 from the chilled gaseous fluid source 601 to create mixture 605 of chilled gaseous fluid 603 and frozen particle mist 604.
  • the mixture 605 is directed through the inflow port(s) to the skin of the patients torso.
  • the mixture 605 then conducts heat transfer across the patients torso, arms and neck removing heat from the patient through the skin to induce a state of hypothermia.
  • the mixture 605 is removed via the at outflow port(s) 612 which are connected to a vacuum source 608.
  • a sensor package 606 may be used to monitor at least one of the following: patient body temperature, target organ temperature, chilled gaseous fluid flow rate, or liquid fluid introduction rate.
  • Data measured by sensor package 606 is used may be used by a processor/controller 607 to modify the production and flow rate of the mixture 605 , the amount of frozen particle mist in mixture 605, and the extraction rate of mist 605 from the suit in order to control the patient's temperature to within targeted therapeutic ranges.
  • a processor/controller 607 may be used to modify the production and flow rate of the mixture 605 , the amount of frozen particle mist in mixture 605, and the extraction rate of mist 605 from the suit in order to control the patient's temperature to within targeted therapeutic ranges.
  • the flow of mixture 605 into the suit and extraction of the mixture 605 from the suit may be independently stopped or restarted by the processor/controller 607.
  • the liquid provided by the various liquid sources is typically water and the mist described in these embodiments is typically a suspension of ice particles. It should be understood that the scope of the invention is not limited to the use of liquid water. Any biocompatible frozen mist suitable for cooling purposes may be used. For instance a froze mist of dry ice may be produced by introducing finely milled dry ice particles into a chilled gas stream in order to produce the chilled fluid frozen mist mixtures described in the above embodiments.
  • the frozen mist comprising the flowing gas stream and the frozen solid particles entrained therein may be introduced into and/or extracted from a patient's abdominal cavity (typically peritoneumor the stomach) using conventional surgical access needles or catheters, such as safety needles (e.g. veress needles), endogastric tubes, and the like.
  • a patient's abdominal cavity typically peritoneumor the stomach
  • conventional surgical access needles or catheters such as safety needles (e.g. veress needles), endogastric tubes, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
EP12829249.7A 2011-09-05 2012-09-05 Gastric or peritoneal delivery of frozen mist to induce therapeutic hyperthermia Not-in-force EP2753273B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531052P 2011-09-05 2011-09-05
PCT/US2012/053809 WO2013036540A1 (en) 2011-09-05 2012-09-05 Gastric, cutaneous, or peritoneal delivery of frozen mist to induce therapeutic hyperthermia

Publications (3)

Publication Number Publication Date
EP2753273A1 EP2753273A1 (en) 2014-07-16
EP2753273A4 EP2753273A4 (en) 2015-05-13
EP2753273B1 true EP2753273B1 (en) 2019-05-01

Family

ID=47832529

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12829249.7A Not-in-force EP2753273B1 (en) 2011-09-05 2012-09-05 Gastric or peritoneal delivery of frozen mist to induce therapeutic hyperthermia

Country Status (5)

Country Link
US (3) US9414959B2 (zh)
EP (1) EP2753273B1 (zh)
JP (1) JP6150802B2 (zh)
CN (1) CN104010598B (zh)
WO (1) WO2013036540A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718256B1 (en) 2004-01-22 2011-12-28 Thermocure Respiratory system for inducing therapeutic hypothermia
US8409184B2 (en) * 2009-09-09 2013-04-02 Cpsi Holdings Llc Cryo-medical injection device and method of use
WO2013036540A1 (en) 2011-09-05 2013-03-14 Thermocure, Inc. Gastric, cutaneous, or peritoneal delivery of frozen mist to induce therapeutic hyperthermia
US10238831B2 (en) * 2013-09-08 2019-03-26 Qool Therapeutics, Inc. Temperature measurement and feedback for therapeutic hypothermia
BR102015002008A2 (pt) * 2015-01-28 2016-08-23 Bernardo Lembo Conde De Paiva cateter
US11020269B2 (en) 2015-02-23 2021-06-01 Qool Therapeutics, Inc. Systems and methods for endotracheal delivery of frozen particles
CN113827819A (zh) * 2016-01-29 2021-12-24 帕格尼亚医疗公司 用于肺递送的干细胞或干细胞衍生物的雾化
EP3554596A4 (en) * 2016-12-13 2020-08-19 Qool Therapeutics, Inc. TRANSPORT OF DENSE PHASE MATERIAL IN A PULMONARY SYSTEM
WO2018187573A1 (en) 2017-04-05 2018-10-11 Arctic Fox Biomedical, Inc. Point of delivery cold slurry generation
KR102589816B1 (ko) 2017-04-05 2023-10-16 미라키 이노베이션 씽크 탱크 엘엘씨 저온 슬러리 격납
US10881424B2 (en) * 2018-02-13 2021-01-05 Covidien Lp Removable fluid reservoir and ultrasonic surgical instrument including the same
US11717656B2 (en) * 2019-03-20 2023-08-08 Gyros ACMI Inc. Delivery of mixed phase media for the treatment of the anatomy
EP4297706A1 (en) * 2021-02-24 2024-01-03 Braincool AB Portable cooling device

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775589B1 (fr) * 1998-03-06 2000-04-28 Cryonic Medical Appareil autonome et portable de cryogenie utilisant l'anhydride carbonique en phase liquide/solide
DE19812075C2 (de) * 1998-03-19 2000-07-06 Paul Haslauer Verfahren zur Erzeugung und/oder zur Verabreichung von Temperatur- und/oder mechanischen Reizen sowie zugehörige Vorrichtung
US5997530A (en) 1998-04-13 1999-12-07 The Regents Of The University Of California Apparatus and method to control atmospheric water vapor composition and concentration during dynamic cooling of biological tissues in conjunction with laser irradiations
JP4148482B2 (ja) 1998-06-03 2008-09-10 株式会社ディード 細氷粒噴射美顔装置
US6303156B1 (en) 1998-06-24 2001-10-16 The Brigham And Women's Hospital Inc. Noninvasive method for increasing or decreasing the body temperature of a patient
US6306119B1 (en) * 1999-01-20 2001-10-23 Pearl Technology Holdings, Llc Skin resurfacing and treatment using biocompatible materials
AU6756300A (en) * 1999-08-02 2001-02-19 Lance B. Becker Method for inducing hypothermia
US6962601B2 (en) * 1999-08-02 2005-11-08 University Of Chicago Office Of Technology Transfer Method for inducing hypothermia
AU2002364893A1 (en) 2001-10-22 2003-06-17 University Of Mississippi Delivery of medicaments to the nail
EP1453524A2 (en) 2001-12-04 2004-09-08 Minnesota High-Tech Resources, LLC Breathable gas mixtures to change body temperature
US20040092920A1 (en) * 2001-12-20 2004-05-13 Eyal Rozenshpeer Cutting and removal of biologic tissue by pressurized propulsion of ice particles
AU2003202237A1 (en) 2002-01-09 2003-07-30 The Brigham And Women's Hospital, Inc. Method for altering the body temperature of a patient using a nebulized mist
US7056282B2 (en) * 2002-12-23 2006-06-06 Medtronic Emergency Response Systems, Inc. Coolant control for rapid induction of mild hypothermia
EP1718256B1 (en) * 2004-01-22 2011-12-28 Thermocure Respiratory system for inducing therapeutic hypothermia
JP2005229297A (ja) 2004-02-12 2005-08-25 Matsushita Electric Ind Co Ltd 音響調整卓
GB0412167D0 (en) 2004-06-01 2004-06-30 Leuven K U Res & Dev Adhesion formation
US7246497B2 (en) * 2004-06-16 2007-07-24 Lytron, Inc. Mist generation, freezing, and delivery system
US7377935B2 (en) * 2004-09-24 2008-05-27 Life Recovery Systems Hd, Llc Apparatus for altering the body temperature of a patient
NZ542067A (en) * 2005-09-29 2006-11-30 David Conrad Clarke Cooling device
US20070093697A1 (en) * 2005-10-21 2007-04-26 Theranova, Llc Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature
US20080097562A1 (en) * 2006-10-19 2008-04-24 Dyamed Biotech Pte Ltd System For Chemohyperthermia Treatment
CN101686872A (zh) * 2007-03-23 2010-03-31 热治疗系统股份有限公司 便携式高热装置
AU2008275158A1 (en) 2007-07-09 2009-01-15 Velomedix, Inc Hypothermia devices and methods
US7819835B2 (en) * 2007-08-07 2010-10-26 Belmont Instrument Corporation Hyperthermia, system, method and components
EP2192879B1 (en) 2007-09-27 2016-05-04 Critical Care Research, Inc. Portable apparatus and method for the administration of heat exchange in the lungs of a mammal
US8256233B2 (en) * 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
EP2373367B1 (en) 2008-12-02 2015-10-21 Qool Therapeutics, Inc. Systems and methods for delivery of a breathing gas with fine ice particles
WO2013036540A1 (en) 2011-09-05 2013-03-14 Thermocure, Inc. Gastric, cutaneous, or peritoneal delivery of frozen mist to induce therapeutic hyperthermia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP6150802B2 (ja) 2017-06-21
US9414959B2 (en) 2016-08-16
CN104010598A (zh) 2014-08-27
CN104010598B (zh) 2015-12-09
JP2014525332A (ja) 2014-09-29
US10238533B2 (en) 2019-03-26
EP2753273A1 (en) 2014-07-16
EP2753273A4 (en) 2015-05-13
US20130085554A1 (en) 2013-04-04
US20160324685A1 (en) 2016-11-10
US20200038237A1 (en) 2020-02-06
WO2013036540A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
US10238533B2 (en) Gastric, cutaneous, or peritoneal delivery of frozen mist to induce therapeutic hyperthermia
US20210346191A1 (en) Respiratory system for inducing therapeutic hypothermia
US20190151142A1 (en) Non-invasive, systems, devices, and methods for selective brain cooling
US10016573B2 (en) Systems and methods for body temperature management
AU2011218179A1 (en) Method and device for non-invasive anatomical and systemic cooling and neuroprotection
US20230010829A1 (en) Patient targeted temperature management device and method
Kobylianskyi et al. The prospects of using thermoelectricity for human head cryotherapy
FRIETSCH Controlled Mild Hypothermia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140312

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150415

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 7/12 20060101ALI20150409BHEP

Ipc: A61F 7/00 20060101ALN20150409BHEP

Ipc: A61F 7/02 20060101AFI20150409BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QOOL THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180105

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602012059686

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61F0007000000

Ipc: A61F0007020000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 7/00 20060101ALN20181109BHEP

Ipc: A61F 7/12 20060101ALI20181109BHEP

Ipc: A61F 7/02 20060101AFI20181109BHEP

INTG Intention to grant announced

Effective date: 20181126

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1125930

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012059686

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190501

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190901

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190801

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190802

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1125930

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012059686

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

26N No opposition filed

Effective date: 20200204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190905

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190905

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120905

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210927

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20210927

Year of fee payment: 10

Ref country code: DE

Payment date: 20210929

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012059686

Country of ref document: DE

Representative=s name: ZACCO LEGAL RECHTSANWALTSGESELLSCHAFT MBH, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012059686

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20220905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220905